Immunovia AB today announced that Massachusetts General Hospital is to participate in PanFAM-1, a multicenter prospective validation study for the early diagnosis in high-risk individuals with Familial Pancreatic Cancer.
Original Article: Massachusetts General Hospital to participate in PanFAM-1 hereditary pancreatic cancer risk study
NEXT ARTICLE